218 related articles for article (PubMed ID: 24719459)
1. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.
Woodham AW; Raff AB; Raff LM; Da Silva DM; Yan L; Skeate JG; Wong MK; Lin YG; Kast WM
J Immunol; 2014 May; 192(10):4748-57. PubMed ID: 24719459
[TBL] [Abstract][Full Text] [Related]
2. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection.
Woodham AW; Da Silva DM; Skeate JG; Raff AB; Ambroso MR; Brand HE; Isas JM; Langen R; Kast WM
PLoS One; 2012; 7(8):e43519. PubMed ID: 22927980
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection.
Woodham AW; Taylor JR; Jimenez AI; Skeate JG; Schmidt T; Brand HE; Da Silva DM; Kast WM
J Antimicrob Chemother; 2015; 70(6):1686-90. PubMed ID: 25712315
[TBL] [Abstract][Full Text] [Related]
4. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Nov; 183(10):6151-6. PubMed ID: 19864613
[TBL] [Abstract][Full Text] [Related]
5. The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context.
Herman L; Hubert P; Herfs M; Kustermans G; Henrotin Y; Bousarghin L; Boniver J; Delvenne P
Eur J Immunol; 2010 Nov; 40(11):3075-84. PubMed ID: 21061438
[TBL] [Abstract][Full Text] [Related]
6. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
[TBL] [Abstract][Full Text] [Related]
7. Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation.
Taylor JR; Fernandez DJ; Thornton SM; Skeate JG; Lühen KP; Da Silva DM; Langen R; Kast WM
Sci Rep; 2018 Aug; 8(1):11642. PubMed ID: 30076379
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
9. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.
Da Silva DM; Woodham AW; Skeate JG; Rijkee LK; Taylor JR; Brand HE; Muderspach LI; Roman LD; Yessaian AA; Pham HQ; Matsuo K; Lin YG; McKee GM; Salazar AM; Kast WM
Clin Immunol; 2015 Dec; 161(2):197-208. PubMed ID: 26360252
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.
Da Silva DM; Movius CA; Raff AB; Brand HE; Skeate JG; Wong MK; Kast WM
Virology; 2014 Mar; 452-453():279-86. PubMed ID: 24606705
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.
Skeate JG; Porras TB; Woodham AW; Jang JK; Taylor JR; Brand HE; Kelly TJ; Jung JU; Da Silva DM; Yuan W; Martin Kast W
J Gen Virol; 2016 Feb; 97(2):422-434. PubMed ID: 26555393
[TBL] [Abstract][Full Text] [Related]
12. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
13. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
[TBL] [Abstract][Full Text] [Related]
14. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
[TBL] [Abstract][Full Text] [Related]
15. The evolving field of human papillomavirus receptor research: a review of binding and entry.
Raff AB; Woodham AW; Raff LM; Skeate JG; Yan L; Da Silva DM; Schelhaas M; Kast WM
J Virol; 2013 Jun; 87(11):6062-72. PubMed ID: 23536685
[TBL] [Abstract][Full Text] [Related]
16. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes.
Caberg JH; Hubert PM; Begon DY; Herfs MF; Roncarati PJ; Boniver JJ; Delvenne PO
Carcinogenesis; 2008 Jul; 29(7):1441-7. PubMed ID: 18566017
[TBL] [Abstract][Full Text] [Related]
17. The cellular endosomal protein stannin inhibits intracellular trafficking of human papillomavirus during virus entry.
Lipovsky A; Erden A; Kanaya E; Zhang W; Crite M; Bradfield C; MacMicking J; DiMaio D; Schoggins JW; Iwasaki A
J Gen Virol; 2017 Nov; 98(11):2821-2836. PubMed ID: 29058661
[TBL] [Abstract][Full Text] [Related]
18. Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes.
Dziduszko A; Ozbun MA
J Virol; 2013 Jul; 87(13):7502-15. PubMed ID: 23637395
[TBL] [Abstract][Full Text] [Related]
19. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody.
Ishii Y; Tanaka K; Kondo K; Takeuchi T; Mori S; Kanda T
Virology; 2010 Oct; 406(2):181-8. PubMed ID: 20684966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
